Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems

被引:18
作者
Liu, Jie [1 ]
Liu, Jinhu [1 ]
Mu, Weiwei [1 ]
Ma, Qingping [1 ]
Zhai, Xiangyu [2 ]
Jin, Bin [2 ,3 ]
Liu, Yongjun [1 ]
Zhang, Na [1 ]
机构
[1] Shandong Univ, Cheeloo Coll Med, Sch Pharmaceut Sci, MInist Educ,Dept Pharmaceut,Key Lab Chem Biol,NMPA, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Second Hosp, Dept Hepatobiliary Surg, Jinan 250033, Shandong, Peoples R China
[3] Shandong Univ, Qilu Hosp, Organ Transplant Dept, Jinan 250012, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Liver fibrosis; Hepatic stellate cell; Nanoparticledrug delivery system; Drug delivery mechanism; Livertargeting; Nanovector; Lipid nanoparticles; Delivery strategy; HEPATIC STELLATE CELLS; NITRIC-OXIDE; CO-DELIVERY; LIPID NANOPARTICLES; ACID; APOPTOSIS; DISEASE; ACCUMULATION; PATHOGENESIS; DEGRADATION;
D O I
10.1021/acsnano.4c02380
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Liver fibrosis (LF) is a pathological repair reaction caused by a chronic liver injury that affects the health of millions of people worldwide, progressing to life-threatening cirrhosis and liver cancer without timely intervention. Due to the complexity of LF pathology, multiple etiological characteristics, and the deposited extracellular matrix, traditional drugs cannot reach appropriate targets in a time-space matching way, thus decreasing the therapeutic effect. Nanoparticle drug delivery systems (NDDS) enable multidrug co-therapy and develop multifactor delivery strategies targeting pathological processes, showing great potential in LF therapy. Based on the pathogenesis and the current clinical treatment status of LF, we systematically elucidate the targeting mechanism of NDDS used in the treatment of LF. Subsequently, we focus on the progress of drug delivery applications for LF, including combined delivery for the liver fibrotic pathological environment, overcoming biological barriers, precise intracellular regulation, and intelligent responsive delivery for the liver fibrotic microenvironment. We hope that this review will inspire the rational design of NDDS for LF in the future in order to provide ideas and methods for promoting LF regression and cure.
引用
收藏
页码:20861 / 20885
页数:25
相关论文
共 204 条
[1]   A human liver cell atlas reveals heterogeneity and epithelial progenitors [J].
Aizarani, Nadim ;
Saviano, Antonio ;
Sagar ;
Mailly, Laurent ;
Durand, Sarah ;
Herman, Josip S. ;
Pessaux, Patrick ;
Baumert, Thomas F. ;
Gruen, Dominic .
NATURE, 2019, 572 (7768) :199-204
[2]   Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms [J].
Akinc, Akin ;
Querbes, William ;
De, Soma ;
Qin, June ;
Frank-Kamenetsky, Maria ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
Rajeev, Kallanthottathil G. ;
Cantley, William L. ;
Dorkin, J. Robert ;
Butler, James S. ;
Qin, LiuLiang ;
Racie, Timothy ;
Sprague, Andrew ;
Fava, Eugenio ;
Zeigerer, Anja ;
Hope, Michael J. ;
Zerial, Marino ;
Sah, Dinah W. Y. ;
Fitzgerald, Kevin ;
Tracy, Mark A. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
de Fougerolles, Antonin ;
Maier, Martin A. .
MOLECULAR THERAPY, 2010, 18 (07) :1357-1364
[3]   Inorganic nanoparticle-based advanced cancer therapies: Promising combination strategies [J].
Amaldoss, Maria John Newton ;
Yang, Jia-Lin ;
Koshy, Pramod ;
Unnikrishnan, Ashwin ;
Sorrell, Charles C. .
DRUG DISCOVERY TODAY, 2022, 27 (12)
[4]  
Amir Muhammad, 2021, Clin Liver Dis (Hoboken), V17, P347, DOI 10.1002/cld.1056
[5]   Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration [J].
Aram, Ghazaleh ;
Potter, James J. ;
Liu, Xiaopu ;
Torbenson, Michael S. ;
Mezey, Esteban .
HEPATOLOGY, 2008, 47 (06) :2051-2058
[6]   Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action [J].
Asrani, Sumeet K. ;
Mellinger, Jessica ;
Arab, Juan P. ;
Shah, Vijay H. .
HEPATOLOGY, 2021, 73 (05) :2039-2050
[7]   Burden of liver diseases in the world [J].
Asrani, Sumeet K. ;
Devarbhavi, Harshad ;
Eaton, John ;
Kamath, Patrick S. .
JOURNAL OF HEPATOLOGY, 2019, 70 (01) :151-171
[8]   Nondegradable Collagen Increases Liver Fibrosis but Not Hepatocellular Carcinoma in Mice [J].
Baglieri, Jacopo ;
Zhang, Cuili ;
Liang, Shuang ;
Liu, Xiao ;
Nishio, Takahiro ;
Rosenthal, Sara B. ;
Dhar, Debanjan ;
Su, Hua ;
Cong, Min ;
Jia, Jidong ;
Hosseini, Mojgan ;
Karin, Michael ;
Kisseleva, Tatiana ;
Brenner, David A. .
AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (09) :1564-1579
[9]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[10]   Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases [J].
Bartneck, Matthias ;
Scheyda, Katharina M. ;
Warzecha, Klaudia T. ;
Rizzo, Larissa Y. ;
Hittatiya, Kanishka ;
Luedde, Tom ;
Storm, Gert ;
Trautwein, Christian ;
Lammers, Twan ;
Tacke, Frank .
BIOMATERIALS, 2015, 37 :367-382